Prospective Study
Copyright ©The Author(s) 2019.
World J Clin Cases. Jun 6, 2019; 7(11): 1291-1301
Published online Jun 6, 2019. doi: 10.12998/wjcc.v7.i11.1291
Table 1 Baseline characteristics of patients in PiCCO and control groups
PiCCO group, n = 30Control group, n = 30P value
Age in yr76.37 ± 6.6775.93 ± 6.550.801
Male18 (60.0%)16 (53.3%)0.602
BMI24.89 ± 2.9024.50 ± 3.520.752
Comorbidities
Hypertension18 (60.0%)15 (50.0%)0.436
Hyperlipidemia8 (26.7%)7 (23.3%)0.766
Diabetes8 (26.7%)7 (23.3%)0.766
Pneumonia8 (26.7%)6 (20.0%)0.542
Respiratory failure3 (10.0%)4 (13.3%)0.688
APACHE II score24.07 ± 6.5426.03 ± 7.000.266
SOFA score10.07 ± 3.3410.09 ± 3.230.330
Hs-TnI in ng/mL0.39 ± 0.320.48 ± 0.320.304
NT-proBNP in pg/mL10459.47 ± 4784.8412871.13 ± 8681.390.189
PaO2/FiO2 in mmHg239.18 ± 96.67252.50 ± 109.640.619
Lac in mmol/L2.32 ± 1.132.40 ± 1.350.820
Table 2 Comparison of APACHE II score, SOFA score, Hs-TnI, NT-proBNP, PaO2/FiO2 and Lac on day 1, 3 and 7 after treatment between PiCCO and control groups
GroupNo.Treatment timeAPACHE II scoreSOFA scoreHs-TnI (ng/mL)NT-proBNP (pg/ml)PaO2/FiO2 (mmHg)Lac (mmol/L)
Control group301 d25.03 ± 7.3511.31 ± 3.570.54 ± 0.3313781.31 ± 9508.70260.32 ± 111.502.41 ± 1.17
3 d22.00 ± 5.619.00 ± 3.390.40 ± 0.3511537.69 ± 9701.62294.94 ± 102.802.30 ± 1.03
7 d17.57 ± 4.897.09 ± 3.340.33 ± 0.289083.04 ± 7702.01341.10 ± 98.051.99 ± 0.70
PiCCO Group301 d21.10 ± 5.95a8.37 ± 3.44b0.34 ± 0.25a8947.00 ± 5739.86a284.05 ± 127.062.15 ± 1.13
3 d17.52 ± 4.88b6.38 ± 3.05b0.17 ± 0.24b7294.83 ± 3638.23a346.96 ± 108.391.80 ± 0.95
7 d11.89 ± 3.38b4.07 ± 2.02b0.11 ± 0.14b5939.14 ± 2396.84a395.36 ± 88.20a1.52 ± 0.74a
Table 3 Infusion and urine volume in patients in PiCCO and control groups
GroupNo.Time frameInfusion volume in mLUrine volume in mL
Control group300-1 d2673.52 ± 945.221895.28 ± 717.58
1-2 d2806.61 ± 724.072111.75 ± 684.02
2-3 d2643.42 ± 674.592199.85 ± 666.83
PiCCO group300-24 h3201.07 ± 967.64a2492.67 ± 868.05b
24-48 h3162.48 ± 770.952363.10 ± 755.36
48-72 h2842.76 ± 765.302502.76 ± 728.34
Table 4 Comparison of primary and secondary outcomes between PiCCO and control groups
PiCCO group, n = 30Control group, n = 30P value
Primary outcome
ADL score66.83 ± 14.6511.33 ± 5.710.000
Secondary outcomes
Days on vasoactive agents10.04 ± 2.5212.09 ± 3.160.013
Duration of mechanical ventilation in d8.13 ± 1.5110.81 ± 2.100.000
Days on MV9.21 ± 4.4012.39 ± 4.140.011
EICU/CCU length of stay12.57 ± 2.7814.83 ± 2.590.005
Pulmonary edema18 (60%)21 (70%)0.589
Table 5 The monitoring indexes of PiCCO group at three point-in-times
Index24 h48 h72 hIntegral analysis
Multiple comparison
Adjustment coefficientsFPP1P2P3
CI in L/min/m22.16 ± 0.432.62 ± 0.392.88 ± 0.910.83513.7230.0010.0000.0000.104
EVLWI in mL/kg8.95 ± 1.857.59 ± 1.456.84 ± 0.821.02421.6690.0000.0010.0000.018
ITBVI in mL/m2972.49 ± 104.28753.91 ± 85.28583.18 ± 65.610.799199.8250.0000.0000.0000.000
GEDVI in mL/m2783.85 ± 88.36604.28 ± 94.11452.29 ± 67.890.948133.4760.0000.0000.0000.000